Study of Stem Cell Transplant for Blood Cancers in Children and Young Adults
This study is looking at a special type of stem cell transplant for children and young adults (ages 6 months to 39 years) with certain blood cancers like acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In this transplant, some cells from the donor's stem cells are removed using a system called Miltenyi CliniMACS Prodigy®. The goal is to see if this modified transplant is safe and effective, and how well it prevents a common complication called acute graft versus host disease (aGVHD). This study plans to include 20 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track the occurrence of acute graft versus host disease (aGVHD) for 100 days after the transplant.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jordan Milner, MD · PRINCIPAL_INVESTIGATOR · University of Florida
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Acute graft versus host disease (aGVHD) incidence100 days
Compare the incidence of grade II to IV aGVHD following allogeneic stem cell trasplantation utilizing α/β CD3+ T-cell and CD19+ B-cell depletion compared to historical controls by day +100